Q - BridgeBio Pharma,
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(353,366) | $(111,704) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 63,123 | 38,511 |
| Losses on extinguishments of debt | 21,155 | 26,590 |
| Accretion of debt | 53,106 | 3,683 |
| Depreciation and amortization | 2,601 | 3,170 |
| Noncash lease expense | 2,230 | 2,093 |
| Net loss from equity method investments | 35,745 | 7,925 |
| Gain on deconsolidation of a subsidiary | — | (126,294) |
| Gain from investment in equity securities, net | — | (8,136) |
| Dividend from investment in equity securities | (2,302) | — |
| Other noncash adjustments, net | (5,464) | (1,911) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (72,146) | 1,091 |
| Inventories | (16,582) | — |
| Prepaid expenses and other current assets | (22,745) | (6,506) |
| Other assets | (174) | 942 |
| Accounts payable | 16,516 | 8,858 |
| Accrued compensation and benefits | (15,637) | (8,378) |
| Accrued research and development liabilities | (2,977) | 7,067 |
| Operating lease liabilities | (3,117) | (2,981) |
| Deferred revenue | (6,491) | 22,236 |
| Other current liabilities | 26,609 | (1,090) |
| Net cash used in operating activities | (279,916) | (144,834) |
| Investing activities: | ||
| Purchases of marketable securities | (7,908) | (93,811) |
| Maturities of marketable securities | — | 55,000 |
| Purchases of investments in equity securities | — | (20,271) |
| Proceeds from sales of investments in equity securities | — | 63,229 |
| Proceeds from special cash dividends received from an investment in equity securities | — | 25,682 |
| Payment for intangible assets | (6,095) | (3,190) |
| Purchases of property and equipment | (594) | (749) |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | — | (98) |
| Net cash provided by (used in) investing activities | (14,597) | 25,792 |
| Financing activities: | ||
| Proceeds from issuance of 2031 Notes | 575,000 | — |
| Issuance costs and discounts associated with 2031 Notes | (12,034) | — |
| Repurchase of common stock | (48,276) | — |
| Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 10) | 300,000 | — |
| Issuance costs associated with royalty obligation under Royalty Purchase Agreement | (2,012) | — |
| Proceeds from term loan under Amended Financing Agreement (as described in Note 9) | — | 450,000 |
| Issuance costs and discounts associated with term loan under Amended Financing Agreement | — | (15,986) |
| Repayment of term loans | (459,000) | (473,417) |
| Repayment of deferred royalty obligation | (2,005) | — |
| Proceeds from issuance of common stock through public offerings, net | — | 314,759 |
| Proceeds from common stock issuances under ESPP | 3,237 | 2,364 |
| Proceeds from stock option exercises, net of repurchases | 9,680 | 778 |
| Transactions with noncontrolling interests | 1,550 | — |
| Repurchase of RSU shares to satisfy tax withholding | (3,771) | (4,679) |
| Net cash provided by financing activities | 362,369 | 273,819 |
| Net increase in cash, cash equivalents and restricted cash | 67,856 | 154,777 |
| Cash, cash equivalents and restricted cash at beginning of period | 683,244 | 394,732 |
| Cash, cash equivalents and restricted cash at end of period | $751,100 | $549,509 |
Condensed Consolidated Statements of Cash Flows
(Continued)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $23,271 | $49,046 |
| Cash paid for income taxes | $1,153 | $— |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Recognized intangible asset recorded to "Other current liabilities" | $2,400 | $— |
| Unpaid public offering issuance costs | $— | $18 |
| Deferred and unpaid issuance costs recorded to “Other current liabilities” | $998 | $74 |
| Unpaid property and equipment | $— | $70 |
| Transfers to noncontrolling interests | $(1,640) | $(1,929) |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $748,953 | $407,958 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 449 | 139,409 |
| Restricted cash — Included in “Other assets” | 1,698 | 2,142 |
| Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows | $751,100 | $549,509 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.